Ibutamoren mesylate
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Research / no approved-treatment claim
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Purported uses, not established benefits
Proponents claim ibutamoren, also called MK-677, may increase growth-hormone signaling, lean mass and recovery.
It is a related non-peptide compound. Changes in lean mass in trials did not establish better strength or physical function, and significant safety concerns remain.
Evidence and source limits
Ibutamoren mesylate poses significant safety risks due to the potential for congestive heart failure in certain patients. The agency is aware of a randomized, placebo-controlled trial assessing ibutamoren mesylate for the treatment of patients recovering from hip fracture that “was terminated early due to a potential safety signal of congestive heart failure.”
This entry records a regulator safety assessment, not a treatment benefit or a clinical recommendation. A research-purpose-only label does not establish safety, FDA approval or permission to use a substance in people. No dosing, supplier or administration guidance is provided.
Original source: Ibutamoren mesylate ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.